{"id":15315,"date":"2023-08-09T23:04:00","date_gmt":"2023-08-09T15:04:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15315"},"modified":"2024-11-27T23:12:22","modified_gmt":"2024-11-27T15:12:22","slug":"bayer-ag-reports-q2-h1-2023-financials-with-challenges-in-crop-science-and-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15315","title":{"rendered":"Bayer AG Reports Q2\/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals"},"content":{"rendered":"\n<p>Germany-based multinational Bayer AG (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR: BAYN<\/a>) has released its financial report for the second quarter and first half of 2023, which indicates the group is facing difficulties due to the performance of its crop science and pharmaceutical business units. The China market, in particular, has been identified as a significant drag on the pharmaceuticals unit. Global group sales for the quarter reached EUR 11.04 billion (USD 12.1 billion), marking an 8.2% year-on-year (YOY) decrease in constant currency terms.<\/p>\n\n\n\n<p><strong>Pharmaceuticals and Consumer Health Sales by Region<\/strong><br>In the pharmaceuticals sector, sales only rose by a modest 0.2% YOY to EUR 4.6 billion (USD 5 billion). The Asia-Pacific region was the only one to report a decline, with sales down 5.2% YOY to EUR 1.4 billion (USD 15.37 billion). In contrast, the consumer health segment reported a more robust 5.4% increase in total sales, reaching EUR 1.466 billion.<\/p>\n\n\n\n<p><strong>Territory-Wise Sales Breakdown<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pharmaceuticals:<\/strong><\/li>\n\n\n\n<li>Europe\/Middle East\/Africa: EUR 1,789 million, up 0.4%<\/li>\n\n\n\n<li>North America: EUR 1,171 million, up 5.0%<\/li>\n\n\n\n<li>Asia-Pacific: EUR 1,356 million, down 5.2%<\/li>\n\n\n\n<li>Latin America: EUR 241 million, up 9.7%<\/li>\n\n\n\n<li>Total: EUR 4,557 million, up 0.27%<\/li>\n\n\n\n<li><strong>Consumer Health:<\/strong><\/li>\n\n\n\n<li>Europe\/Middle East\/Africa: EUR 448 million, up 5.2%<\/li>\n\n\n\n<li>North America: EUR 594 million, up 0.7%<\/li>\n\n\n\n<li>Asia-Pacific: EUR 228 million, up 3.0%<\/li>\n\n\n\n<li>Latin America: EUR 196 million, up 24.1%<\/li>\n\n\n\n<li>Total: EUR 1,466 million, up 5.4%<\/li>\n<\/ul>\n\n\n\n<p><strong>Source: Bayer<\/strong><\/p>\n\n\n\n<p><strong>Market Performance and Impact of Volume-Based Procurement (VBP)<\/strong><br>Stefan Oelrich, President of the Pharmaceuticals Division, addressed the market performance during an earnings conference call, highlighting China as a key factor in the Asia-Pacific slowdown. He cited a softer-than-anticipated post-pandemic recovery in China and ongoing challenges from volume-based procurement related headwinds. The VBP tendering process continued to impact global sales of blood thinner Xarelto (rivaroxaban), which fell by 3% during the quarter. Angina treatment Adalat (nifedipine) also faced difficulties due to VBP impact.<\/p>\n\n\n\n<p><strong>Contrasting Portfolio Performance and Outlook<\/strong><br>Oelrich noted a split in the company\u2019s portfolio performance, with off-patent brands experiencing a slowdown, even without VBP impact, while innovative drugs have thrived. Notably, prostate cancer treatment Nubeqa (darolutamide) and chronic kidney disease drug Kerendia (finerenone) benefited from immediate inclusion in the National Reimbursement Drug List (NRDL) upon approval. Nubeqa\u2019s local launch was described as \u201cextremely strong,\u201d with China emerging as the strongest market share geography for the drug. However, due to the overall China performance, Bayer has downgraded its forecast for the Pharmaceutical unit\u2019s full-year growth performance to 0% YOY, from a previous prediction of a 1% expansion.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[269,967,27],"class_list":["post-15315","post","type-post","status-publish","format-standard","hentry","category-company","tag-bayer","tag-etr-bayn","tag-finanical-reports"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer AG Reports Q2\/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter and first half of 2023, which indicates the group is facing difficulties due to the performance of its crop science and pharmaceutical business units. The China market, in particular, has been identified as a significant drag on the pharmaceuticals unit. Global group sales for the quarter reached EUR 11.04 billion (USD 12.1 billion), marking an 8.2% year-on-year (YOY) decrease in constant currency terms.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15315\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer AG Reports Q2\/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15315\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-09T15:04:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-27T15:12:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15315#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15315\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer AG Reports Q2\\\/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals\",\"datePublished\":\"2023-08-09T15:04:00+00:00\",\"dateModified\":\"2024-11-27T15:12:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15315\"},\"wordCount\":396,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Bayer\",\"ETR: BAYN\",\"Finanical Reports\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15315#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15315\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15315\",\"name\":\"Bayer AG Reports Q2\\\/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-09T15:04:00+00:00\",\"dateModified\":\"2024-11-27T15:12:22+00:00\",\"description\":\"Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter and first half of 2023, which indicates the group is facing difficulties due to the performance of its crop science and pharmaceutical business units. The China market, in particular, has been identified as a significant drag on the pharmaceuticals unit. Global group sales for the quarter reached EUR 11.04 billion (USD 12.1 billion), marking an 8.2% year-on-year (YOY) decrease in constant currency terms.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15315#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15315\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15315#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer AG Reports Q2\\\/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer AG Reports Q2\/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals - Insight, China&#039;s Pharmaceutical Industry","description":"Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter and first half of 2023, which indicates the group is facing difficulties due to the performance of its crop science and pharmaceutical business units. The China market, in particular, has been identified as a significant drag on the pharmaceuticals unit. Global group sales for the quarter reached EUR 11.04 billion (USD 12.1 billion), marking an 8.2% year-on-year (YOY) decrease in constant currency terms.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15315","og_locale":"en_US","og_type":"article","og_title":"Bayer AG Reports Q2\/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15315","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-09T15:04:00+00:00","article_modified_time":"2024-11-27T15:12:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15315#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15315"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer AG Reports Q2\/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals","datePublished":"2023-08-09T15:04:00+00:00","dateModified":"2024-11-27T15:12:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15315"},"wordCount":396,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Bayer","ETR: BAYN","Finanical Reports"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15315#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15315","url":"https:\/\/flcube.com\/?p=15315","name":"Bayer AG Reports Q2\/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-09T15:04:00+00:00","dateModified":"2024-11-27T15:12:22+00:00","description":"Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter and first half of 2023, which indicates the group is facing difficulties due to the performance of its crop science and pharmaceutical business units. The China market, in particular, has been identified as a significant drag on the pharmaceuticals unit. Global group sales for the quarter reached EUR 11.04 billion (USD 12.1 billion), marking an 8.2% year-on-year (YOY) decrease in constant currency terms.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15315#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15315"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15315#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer AG Reports Q2\/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15315"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15315\/revisions"}],"predecessor-version":[{"id":15316,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15315\/revisions\/15316"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}